Log In
Print
BCIQ
Print
Print this Print this
 

2H10

  Manage Alerts
Collapse Summary General Information
Company CSL Ltd.
DescriptionNeutralizing mAb against VEGF-B
Molecular Target Vascular endothelial growth factor B (VEGF-B)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today